Skip to main content
OpenTrials
Completed

NCT Number: NCT03855969

Central Venous Access Device Removal in Cancer Patients

Background:

Central venous catheters are frequently used during cancer treatment with the aim of venepreservation. It can facilitate venous access for the safe administration of irritating or vesicant intravenous cancer medications and / or other fluids, to collect blood samples or to ensure accurate venous access for contrast during medical imaging. In addition, this means more comfort for the patient who needs to be punctured less peripherally. However, central venous catheters can also be a source of bloodstream infections and other complications, leading to increased morbidity and hospital costs (1). In our hospital, there is a general practice that if an infection of the device is suspected, the central venous catheter should be removed if antibiotics do not seem or prove to be effective.

The objective of this trial is to assess the frequency of implanted port catheter-removal in cancer patients due to suspected infection of the device in a particular oncology center over a time period of seven years. Furthermore, evidence for real device infections (per/post-surgery) and the potential contribution of different (institution-specific) risk factors on device infection will be explored. There will be focused on implanted port catheters only, as this is the main used central venous access device within the oncological population.

Trial objectives:

The primary aim of this retrospective descriptive trial is to evaluate the frequency of implanted port catheter-removal in cancer patients due to suspected infection of the device, over a time period of seven years.

The secondary aim is to examine whether the device infection could be confirmed during or after removal of the device.

At last, the tertiary aim is to verify whether certain variables can be denoted as potential risk factors for central venous access infection. Selection of those variables of interest will be based on a thorough review of the literature and discussion with the responsible healthcare professionals.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

GHGroeninge

Kortrijk, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Central venous access device removal in our general hospital
  • Cancer patient

Exclusion criteria

-

Treatment and study plan

Removal of a central venous access device

Procedure

We are interested in those patients for which a central venous access device was removed.

Primary outcomes

  1. Suspected infection rate

    Time frame: 2012-2017

    How many central venous access devices are removed due to a suspected infection of the device in cancer patients.

Secondary outcomes

  1. Approved infection rate

    Time frame: 2012-2017

    For how many of the central venous access devices that were removed due to suspected infection of the device could an infection be confirmed?

  2. Risk factors for central venous access device infections in cancer patients

    Time frame: 2012-2017

    Is it possible to denote certain variables as potential risk factors for central venous access device infection?

Sponsors and collaborators

Lead sponsor

General Hospital Groeninge

Other

Registry information

Official study title

Frequency of Central Venous Port Catheter Removal Due to Suspected Infection in Patients Diagnosed With Cancer at a Single Institution: A Retrospective Study.

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Feb 27, 2019
Registry last updated
Aug 5, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.